Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol
(BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to
fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients
switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared
with patients not switched.